Toma Bogdan, Caruntu Irina-Draga, Simionescu Natalia, Onofriescu Mircea, Socolov Demetra, Ilea Ciprian, Chifu Bianca, Giusca Simona-Eliza, Timofte Andrei Daniel, Tirnovanu Mihaela, Socolov Razvan
Department of Morpho-Functional Sciences I, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iași, Romania.
"Cuza Vodă" Clinical Hospital of Obstetrics and Gynecology, 700038 Iași, Romania.
Medicina (Kaunas). 2025 Sep 15;61(9):1671. doi: 10.3390/medicina61091671.
: Endometriosis, a complex and often underdiagnosed gynecological condition, frequently manifests with ovarian involvement, posing significant clinical challenges. Current diagnostic protocols primarily rely on invasive techniques, thus highlighting the critical need for reliable, non-invasive biomarkers. This study aimed to evaluate the diagnostic performance and clinical relevance of Urocortin and Histone H4, assessed in both serum and urine, as potential biomarkers for ovarian endometriosis. : We implemented an exploratory study design to investigate potential biomarkers for ovarian endometriosis. The study cohort consisted of 40 women, divided into three groups: Those with histologically confirmed ovarian endometriosis are 30, those with parietal endometriosis are 5, and 5 healthy controls. Standardized ELISA protocols were employed for the quantification of Urocortin and Histone H4 in both serum and urine samples. To ensure consistency, all participants were assessed during the proliferative phase of their menstrual cycle. Finally, comparative and multivariate statistical analyses were conducted to evaluate biomarker variability in the context of relevant clinical parameters. : Serum Urocortin levels were comparable across the three groups (mean ± SD: 3.63 ± 0.41 µg/mL in ovarian endometriosis vs. 3.59 ± 0.31 µg/mL in parietal endometriosis and 3.70 ± 0.38 µg/mL in controls; > 0.05). In contrast, urinary Urocortin levels were significantly elevated in patients with ovarian endometriosis (2.51 ± 1.36 µg/mL), compared to both parietal endometriosis (0.13 ± 0.04 µg/mL) and controls (0.33 ± 0.18 µg/mL; = 0.001). Multivariate linear regression revealed that age, age at menarche, and disease duration accounted for 28.3% of the variance in urinary Urocortin levels (adjusted R = 0.283; = 0.002). Serum Histone H4 concentrations were modestly elevated in the ovarian endometriosis group (0.49 ± 0.18 ng/mL), although no statistically significant intergroup differences were observed. Urinary Histone H4 levels showed subtle variation but lacked discriminatory value. : Urinary Urocortin showed a preliminary diagnostic signal in this small exploratory cohort, whereas Histone H4 did not perform significantly. Our findings require replication in larger, multicenter, and rigorously controlled studies with validated urine normalization methods. Nonetheless, our study opens further perspectives for complementing the biomarker panel with potential non-invasive diagnostic value with new candidates.
子宫内膜异位症是一种复杂且常被漏诊的妇科疾病,常累及卵巢,带来重大临床挑战。目前的诊断方案主要依赖侵入性技术,因此凸显了对可靠的非侵入性生物标志物的迫切需求。本研究旨在评估在血清和尿液中检测的尿皮质素和组蛋白H4作为卵巢子宫内膜异位症潜在生物标志物的诊断性能及临床相关性。
我们采用探索性研究设计来调查卵巢子宫内膜异位症的潜在生物标志物。研究队列由40名女性组成,分为三组:组织学确诊为卵巢子宫内膜异位症的有30名,腹壁子宫内膜异位症的有5名,以及5名健康对照。采用标准化酶联免疫吸附测定(ELISA)方案对血清和尿液样本中的尿皮质素和组蛋白H4进行定量。为确保一致性,所有参与者均在月经周期的增殖期进行评估。最后,进行比较和多变量统计分析,以评估相关临床参数背景下生物标志物的变异性。
三组的血清尿皮质素水平相当(均值±标准差:卵巢子宫内膜异位症组为3.63±0.41μg/mL,腹壁子宫内膜异位症组为3.59±0.31μg/mL,对照组为3.70±0.38μg/mL;P>0.05)。相比之下,卵巢子宫内膜异位症患者的尿皮质素水平显著升高(2.51±1.36μg/mL),与腹壁子宫内膜异位症患者(0.13±0.04μg/mL)和对照组(0.33±0.18μg/mL)相比,差异有统计学意义(P=0.001)。多变量线性回归显示,年龄、初潮年龄和病程占尿皮质素水平变异的28.3%(调整后R²=0.283;P=0.002)。卵巢子宫内膜异位症组的血清组蛋白H4浓度略有升高(0.49±0.18ng/mL),但组间未观察到统计学上的显著差异。尿组蛋白H4水平有细微变化,但缺乏鉴别价值。
在这个小型探索性队列中,尿皮质素显示出初步诊断信号,而组蛋白H4表现不显著。我们的研究结果需要在更大规模、多中心且严格控制的研究中,采用经过验证的尿液标准化方法进行重复验证。尽管如此,我们的研究为用具有潜在非侵入性诊断价值的新候选物补充生物标志物组合开辟了进一步的前景。